- Home
- CATX
as 05-09-2025 4:00pm EST
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
Upcoming Earnings Alert:
Get ready for potential market movements as Perspective Therapeutics Inc. CATX prepares to release earnings report on 12 May 2025.
| Founded: | 1983 | Country: | United States |
| Employees: | N/A | City: | SEATTLE |
| Market Cap: | 182.9M | IPO Year: | N/A |
| Target Price: | $13.89 | AVG Volume (30 days): | 619.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.23 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.60 - $19.10 | Next Earning Date: | 05-12-2025 |
| Revenue: | $1,454,000 | Revenue Growth: | 1.40% |
| Revenue Growth (this year): | -53.08% | Revenue Growth (next year): | -18.88% |
Stock Insider Trading Activity of Perspective Therapeutics Inc. (CATX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Woods Lori A | CATX | Director | Mar 31 '25 | Buy | $2.13 | 23,475 | $49,999.40 | 183,460 | |
| Graham Juan | CATX | Chief Financial Officer | Mar 28 '25 | Buy | $2.25 | 33,333 | $74,945.92 | 35,354 | |
| Williamson Robert F III | CATX | Director | Mar 28 '25 | Buy | $2.21 | 60,337 | $132,151.09 | 70,837 | |
| Spoor Johan M. | CATX | Chief Executive Officer | Mar 28 '25 | Buy | $2.23 | 26,676 | $59,672.62 | 59,383 |
Latest Perspective Therapeutics Inc. News
CATX Breaking Stock News: Dive into CATX Ticker-Specific Updates for Smart Investing
GlobeNewswire
8 days ago
Perspective Therapeutics to Participate in Upcoming May Investor Conferences
MT Newswires
10 days ago
Perspective Therapeutics Treats First Patient in Phase 1/2a Trial for Solid Tumors
GlobeNewswire
10 days ago
Perspective Therapeutics Announces First Patient Dosed with PSV359 in a Phase 1/2a Study in Patients with FAP-α Positive Solid Tumors
GlobeNewswire
16 days ago
Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting
Zacks
16 days ago
Journey Medical (DERM) Moves 16.8% Higher: Will This Strength Last?
GlobeNewswire
22 days ago
Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results
MT Newswires
a month ago
Perspective Therapeutics Doses First Patient in New Melanoma Trial Cohort With [212Pb]VMT01 Monotherapy
![Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma](https://cdn.finquota.com/news/e6ed3cbf-c3fa-4ebc-9a1a-b2ea4f270cb1.jpg)
GlobeNewswire
a month ago
Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma
Compare CATX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CATX Perspective Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.